BIOMAT Database Logo BIOMAT Database Logo

Outpatient overnight glucose control with dual-hormone artificial pancreas, single-hormone artificial pancreas, or conventional insulin pump therapy in children and adolescents with type 1 diabetes: an open-label, randomised controlled trial. 2015

Ahmad Haidar, and Laurent Legault, and Laurence Matteau-Pelletier, and Virginie Messier, and Maryse Dallaire, and Martin Ladouceur, and Rémi Rabasa-Lhoret
Institut de recherches cliniques de Montréal, Montreal, QC, Canada; Division of Experimental Medicine, Department of Medicine, McGill University, Montreal, QC, Canada. Electronic address: ahmad.haidar@mail.mcgill.ca.

BACKGROUND Additional benefits of the dual-hormone (insulin and glucagon) artificial pancreas compared with the single-hormone (insulin alone) artificial pancreas have not been assessed in young people in outpatient unrestricted conditions. We evaluated the efficacy of three systems for nocturnal glucose control in children and adolescents with type 1 diabetes. METHODS We did a randomised, three-way, crossover trial in children aged 9-17 years with type 1 diabetes attending a diabetes camp in Canada. With use of sealed envelopes, children were randomly assigned in a 1:1:1:1:1:1 ratio with blocks of six to different sequences of the three interventions (single-hormone artificial pancreas, dual-hormone artificial pancreas, and conventional continuous subcutaneous insulin pump therapy). Each intervention was applied for 3 consecutive nights. Participants, study staff, and endpoint assessors were not masked. The primary outcome was the percentage of time spent with glucose concentrations lower than 4·0 mmol/L from 2300 h to 0700 h. Analysis was by intention to treat. A p value of less than 0·0167 was regarded as significant. This study is registered with ClinicalTrials.gov, number NCT02189694. RESULTS Between June 30, 2014, and Aug 9, 2014, we enrolled 33 children of mean age 13·3 years (SD 2·3; range 9-17). The time spent at a glucose concentration lower than 4·0 mmol/L was median 0% (IQR 0·0-2·4) during nights with the dual-hormone artificial pancreas, 3·1% (0·0-6·9) during nights with the single-hormone artificial pancreas (p=0·032), and 3·4% (0-11·0) during nights with conventional pump therapy (p=0·0048 compared with dual-hormone artificial pancreas and p=0·32 compared with single-hormone artificial pancreas). 15 hypoglycaemic events (<3·1 mmol/L for 20 min measured by sensor then confirmed with capillary glucose <4·0 mmol/L) were noted during nights with conventional pump therapy compared with four events with the single-hormone system and no events with the dual-hormone system. None of the assessed outcomes varied with the order in which children and young adults were assigned interventions. CONCLUSIONS The dual-hormone artificial pancreas could improve nocturnal glucose control in children and adolescents with type 1 diabetes. Longer and larger outpatient studies are now needed. BACKGROUND Canadian Diabetes Association, Fondation J A De Sève.

UI MeSH Term Description Entries
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D007332 Insulin Infusion Systems Portable or implantable devices for infusion of insulin. Includes open-loop systems which may be patient-operated or controlled by a pre-set program and are designed for constant delivery of small quantities of insulin, increased during food ingestion, and closed-loop systems which deliver quantities of insulin automatically based on an electronic glucose sensor. Pancreas, Artificial Endocrine,Programmable Implantable Insulin Pump,beta Cell, Artificial,Implantable Programmable Insulin Pump,Insulin Pump, Programmable Implantable,Pump, Programmable Implantable Insulin,Artificial Endocrine Pancreas,Artificial beta Cell,Artificial beta Cells,Cell, Artificial beta,Cells, Artificial beta,Endocrine Pancreas, Artificial,Infusion System, Insulin,Infusion Systems, Insulin,Insulin Infusion System,System, Insulin Infusion,Systems, Insulin Infusion,beta Cells, Artificial
D008297 Male Males
D010045 Outpatients Persons who receive ambulatory care at an outpatient department or clinic without room and board being provided. Out-patients,Out patients,Out-patient,Outpatient
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D002170 Canada The largest country in North America, comprising 10 provinces and three territories. Its capital is Ottawa.
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D003922 Diabetes Mellitus, Type 1 A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence. Diabetes Mellitus, Brittle,Diabetes Mellitus, Insulin-Dependent,Diabetes Mellitus, Juvenile-Onset,Diabetes Mellitus, Ketosis-Prone,Diabetes Mellitus, Sudden-Onset,Diabetes, Autoimmune,IDDM,Autoimmune Diabetes,Diabetes Mellitus, Insulin-Dependent, 1,Diabetes Mellitus, Type I,Insulin-Dependent Diabetes Mellitus 1,Juvenile-Onset Diabetes,Type 1 Diabetes,Type 1 Diabetes Mellitus,Brittle Diabetes Mellitus,Diabetes Mellitus, Insulin Dependent,Diabetes Mellitus, Juvenile Onset,Diabetes Mellitus, Ketosis Prone,Diabetes Mellitus, Sudden Onset,Diabetes, Juvenile-Onset,Diabetes, Type 1,Insulin Dependent Diabetes Mellitus 1,Insulin-Dependent Diabetes Mellitus,Juvenile Onset Diabetes,Juvenile-Onset Diabetes Mellitus,Ketosis-Prone Diabetes Mellitus,Sudden-Onset Diabetes Mellitus
D005260 Female Females
D005934 Glucagon A 29-amino acid pancreatic peptide derived from proglucagon which is also the precursor of intestinal GLUCAGON-LIKE PEPTIDES. Glucagon is secreted by PANCREATIC ALPHA CELLS and plays an important role in regulation of BLOOD GLUCOSE concentration, ketone metabolism, and several other biochemical and physiological processes. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1511) Glucagon (1-29),Glukagon,HG-Factor,Hyperglycemic-Glycogenolytic Factor,Proglucagon (33-61),HG Factor,Hyperglycemic Glycogenolytic Factor

Related Publications

Ahmad Haidar, and Laurent Legault, and Laurence Matteau-Pelletier, and Virginie Messier, and Maryse Dallaire, and Martin Ladouceur, and Rémi Rabasa-Lhoret
Overnight closed loop insulin delivery (artificial pancreas) in adults with type 1 diabetes: crossover randomised controlled studies.
April 2011, BMJ (Clinical research ed.),
Ahmad Haidar, and Laurent Legault, and Laurence Matteau-Pelletier, and Virginie Messier, and Maryse Dallaire, and Martin Ladouceur, and Rémi Rabasa-Lhoret
Day and night glycaemic control with a bionic pancreas versus conventional insulin pump therapy in preadolescent children with type 1 diabetes: a randomised crossover trial.
March 2016, The lancet. Diabetes & endocrinology,
Ahmad Haidar, and Laurent Legault, and Laurence Matteau-Pelletier, and Virginie Messier, and Maryse Dallaire, and Martin Ladouceur, and Rémi Rabasa-Lhoret
Day-and-night glycaemic control with closed-loop insulin delivery versus conventional insulin pump therapy in free-living adults with well controlled type 1 diabetes: an open-label, randomised, crossover study.
April 2017, The lancet. Diabetes & endocrinology,
Ahmad Haidar, and Laurent Legault, and Laurence Matteau-Pelletier, and Virginie Messier, and Maryse Dallaire, and Martin Ladouceur, and Rémi Rabasa-Lhoret
Dual-hormone artificial pancreas for glucose control in type 1 diabetes: A meta-analysis.
October 2022, Diabetes, obesity & metabolism,
Ahmad Haidar, and Laurent Legault, and Laurence Matteau-Pelletier, and Virginie Messier, and Maryse Dallaire, and Martin Ladouceur, and Rémi Rabasa-Lhoret
Suspended insulin infusion during overnight closed-loop glucose control in children and adolescents with Type 1 diabetes.
April 2010, Diabetic medicine : a journal of the British Diabetic Association,
Ahmad Haidar, and Laurent Legault, and Laurence Matteau-Pelletier, and Virginie Messier, and Maryse Dallaire, and Martin Ladouceur, and Rémi Rabasa-Lhoret
Efficacy and safety of suspend-before-low insulin pump technology in hypoglycaemia-prone adults with type 1 diabetes (SMILE): an open-label randomised controlled trial.
June 2019, The lancet. Diabetes & endocrinology,
Ahmad Haidar, and Laurent Legault, and Laurence Matteau-Pelletier, and Virginie Messier, and Maryse Dallaire, and Martin Ladouceur, and Rémi Rabasa-Lhoret
The use and efficacy of continuous glucose monitoring in type 1 diabetes treated with insulin pump therapy: a randomised controlled trial.
December 2012, Diabetologia,
Ahmad Haidar, and Laurent Legault, and Laurence Matteau-Pelletier, and Virginie Messier, and Maryse Dallaire, and Martin Ladouceur, and Rémi Rabasa-Lhoret
Fully Closed Loop Glucose Control With a Bihormonal Artificial Pancreas in Adults With Type 1 Diabetes: An Outpatient, Randomized, Crossover Trial.
March 2021, Diabetes care,
Ahmad Haidar, and Laurent Legault, and Laurence Matteau-Pelletier, and Virginie Messier, and Maryse Dallaire, and Martin Ladouceur, and Rémi Rabasa-Lhoret
[Remission of diabetes during conventional insulin therapy or therapy controlled by use of an artificial pancreas].
January 1979, La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris,
Ahmad Haidar, and Laurent Legault, and Laurence Matteau-Pelletier, and Virginie Messier, and Maryse Dallaire, and Martin Ladouceur, and Rémi Rabasa-Lhoret
A randomized controlled trial of insulin pump therapy in young children with type 1 diabetes.
June 2005, Diabetes care,
Copied contents to your clipboard!